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Abstract 
Colorectal cancer is the second leading cause of cancer-
related mortality among U.S. adults. In 2004, treatment 
costs for colorectal cancer were $8.4 billion.
There is substantial evidence that colorectal cancer inci-
dence and mortality are reduced with regular screening. 
The natural history of this disease is also well described: 
most colorectal cancers develop slowly from preexisting 
polyps. This slow development provides an opportunity to 
intervene with screening tests, which can either prevent 
colorectal cancer through the removal of polyps or detect it 
at an early stage. However, much less is known about how 
best to implement an effective colorectal cancer screening 
program. Screening rates are low, and uninsured persons, 
low-income persons, and persons who have not visited a 
physician within a year are least likely to be screened.
Although the Centers for Disease Control and Prevention 
(CDC) has 15 years of experience supporting the National 
Breast and Cervical Cancer Early Detection Program for 
the underserved population, a similar national program for 
colorectal cancer is not in place. To explore the feasibility 
of implementing a national program for the underserved 
U.S. population and to learn which settings and which 
program models are most viable and cost-effective, CDC 
began a 3-year colorectal cancer screening demonstration 
program in 2005.
This article describes briefly this demonstration program 
and the process CDC used to design it and to select pro-
gram sites. The multiple-methods evaluation now under 
way to assess the program’s feasibility and describe key 
outcomes is also detailed. Evaluation results will be used 
to inform future activities related to organized screening 
for colorectal cancer.
Introduction 
Cancer is the second leading cause of death among U.S. 
adults, and colorectal cancer is the second leading cause 
of cancer-related deaths among U.S. men and women. In 
2004, there were 145,083 new cases of colorectal cancer, 
and 53,580 people died of the disease (1). Although colorec-
tal cancer affects both sexes and all races, men, African 
Americans, and Alaska Natives have disproportionately 
high incidences and mortality rates of colorectal cancer (2). 
In addition, colorectal cancer is expensive to treat: in 2004, 
the national cost of medical treatment for this disease was 
$8.4 billion (3).
Most colorectal cancers develop slowly from pre-existing 
polyps. This slow development provides an opportunity to 
intervene with screening tests, which can either prevent 
colorectal cancer through the removal of polyps or detect it 
at an early stage (4). Substantial scientific evidence shows 
that the incidence and mortality are reduced by regular 
screening (5-10). However, screening rates have been slow 
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to increase (11), and it is not clear how best to implement an 
effective colorectal cancer screening program that reaches 
the people most in need. Uninsured persons, low-income 
persons, or those who have not seen a physician within the 
previous year are least likely to be screened (11).
The Centers for Disease Control and Prevention (CDC) 
has 15 years of experience supporting the National Breast 
and Cervical Cancer Early Detection Program (NBCCEDP) 
for the medically underserved population, but a similar 
national program for colorectal cancer is not in place (12). 
The NBCCEDP uses a comprehensive approach to breast 
and cervical cancer control, which includes providing 
early detection services, educational activities, public and 
private partnerships, and quality assurance measures. 
Clinically, screening for colorectal cancer is more complex 
than screening for either breast or cervical cancer because 
several screening tests are acceptable, each with a differ-
ent recommended interval and each performed by differ-
ent types of health care specialists. To understand better 
how to structure and implement population-level colorec-
tal cancer screening and to explore which settings and 
program models are most viable and cost-effective, CDC 
began a 3-year colorectal cancer screening demonstration 
program in 2005. It was designed for low-income persons 
aged 50 to 64 years who are underinsured or uninsured for 
colorectal cancer screening.
This article describes briefly the process used to 
establish the CDC-funded Colorectal Cancer Screening 
Demonstration Program and the tools developed to imple-
ment this program. In accompanying reports in this issue 
of Preventing Chronic Disease (13-15), we present case-
study and cost-study evaluation findings from the pro-
gram start-up period, which we defined as beginning when 
the demonstration sites received their initial funds and 
ending when the screening itself began. Future reports 
will include evaluation results from the implementation 
phase of the program.
Program Planning Process 
In the summer of 2004, CDC held two meetings with 58 
invited stakeholders, including clinicians and health sci-
entists from CDC, other federal health agencies, partner 
organizations such as the American Cancer Society and 
Prevent Cancer Foundation, state health departments, 
and health systems such as managed care organizations. 
Also in attendance were representatives from Australia, 
the United Kingdom, and Italy, many with experience in 
organized colorectal cancer screening programs. During 
these stakeholder meetings, we used published data, the 
combined experience of meeting attendees, and consensus 
opinion to make key decisions that helped define the dem-
onstration program. These decisions included:
Applicants for funds to implement a screening 
program could be any nonprofit medical entity that 
offered services to low-income persons who are 
underinsured for colorectal cancer screening.
When possible, screening programs would be flex-
ible in their structure and design so they could 
meet the needs of the community they intended to 
serve.
Applicants would need to actively collaborate with 
their state’s CDC-funded Comprehensive Cancer 
Control Program.
Because the U.S. Preventive Services Task Force 
(USPSTF) (16) recommends four screening tests 
with no one “best” test recommended, applicants 
proposing a screening program could choose which 
colorectal cancer screening tests to offer as long as
• The selected test or tests are recommended by 
USPSTF.
• The applicant has the capacity to offer the select-
ed test or tests.
Providers within each selected program would be 
reimbursed for screening and diagnostic tests at 
the Medicare rate.
The focus of the screening programs would be on 
people aged 50 to 64 at average risk for colorectal 
cancer; younger persons would be eligible if they 
are at increased risk.
• Persons at increased risk for colorectal cancer 
because of a personal or family history of this 
disease would be eligible to receive screening 
services.
• Persons with colorectal cancer symptoms or 
at high risk of colorectal cancer because they 
already have inflammatory bowel disease or 
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certain genetic conditions would not be eligible 
to receive services, because these conditions 
require frequent specialized care.
Programs would need to convene a local medical 
advisory board to address ongoing clinical issues.
As with the NBCCEDP, CDC funds would not be 
used for cancer treatment. To be eligible for con-
sideration, applicants had to identify, in advance, 
sources that would provide treatment services for 
1) cancers detected through the screening program 
and 2) complications that may arise during screen-
ing and diagnostic procedures.
Site Selection and Program Features 
Of the 39 applicants who competed for funds to start 
a demonstration project, 5 were selected and awarded 
a combined $2.1 million for year 1 of a 3-year program 
beginning in 2005. The successful applicants were the 
Maryland Department of Health and Mental Hygiene; 
Missouri Department of Health and Senior Services; 
Nebraska Department of Health and Human Services; 
Public Health – Seattle & King County, Washington; and 
Stony Brook University Medical Center, New York. The 
program’s structure and the screening tests selected for 
the program are described in the Figure.
Each of the five programs is described in this issue of 
Preventing Chronic Disease (14). Program components in 
the five selected sites include clinical services (screening, 
surveillance, and diagnostic services), patient support, 
data collection and tracking, program management, public 
education and outreach, quality services measures, part-
nerships, and evaluation of program process and effective-
ness. A multidisciplinary CDC team worked closely with 
the five selected sites during their start-up; the team 
included physicians, public health advisors, epidemi-
ologists, program analysts, evaluators, health economists, 
data consultants, and health communications specialists.
Materials Developed for the Colorectal 
Cancer Screening Program 
During the start-up phase, which ranged from 9 to 
11 months, CDC staff and program staff at each site 
collaborated to develop the program’s materials and 
components. These include policies, a set of standard 
data elements (colorectal cancer clinical data elements or 
CCDEs), a data user’s manual, data collection forms, a 
readiness checklist, a cost-assessment tool, and an evalu-
ation plan. The cost-assessment tool and evaluation plan 
are described in another article in this issue of Preventing 
Chronic Disease (15). The readiness checklist, program 
policies, CCDEs, and data users’ manual are available at 
http://www.cdc.gov/cancer/colorectal/what_cdc_is_doing/
demonstration/. Data collection forms were designed 
individually by each program site and are available on 
request.
Program policies 
CDC created a policy manual for this demonstration 
program. Each site also created its own individual poli-
cies, which usually mirrored the policies that CDC creat-
ed for the overall program. Policies were developed on the 
following topics: 1) patient eligibility, 2) reimbursement, 
3) reporting adverse events, 4) collecting and reporting 
data, and 5) medical advisory committees. A series of sup-
porting documents to accompany the policy manual were 
developed by CDC in collaboration with all sites. These 
documents include guidelines for patient eligibility and 
ineligibility, reimbursable clinical services, data reporting 
requirements and schedules, and service quality indica-
tors. These indicators were developed to capture data 
on the characteristics of the population being served by 
the program, the completeness of clinical follow-up and 
treatment, and the timeliness of clinical follow-up and 
treatment.
Colorectal Cancer Clinical Data Elements 
The CCDEs were developed by CDC, program sites, 
and two external clinical experts to ensure that informa-
tion collected about clients’ demographic characteristics, 
screening history, risk factors, screening and diagnostic 
tests, final diagnosis, and treatment would be consistent 
and complete. These data will be used to monitor the 
extent to which the five demonstration sites achieve the 
objectives of the demonstration project. They will also be 
used to guide future policy and program development. 
CDC provided technical assistance on data management 
and reporting to each of the five sites through routine 
communication and through tools that promote stan-
dard reporting, including a communication Web site for 
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Maryland Department of Health and Mental Hygiene 
• Site of the colorectal cancer screening program: Baltimore
• Service delivery network: five hospitals
• Screening test offered: primary screening with colonoscopy
Missouri Department of Health and Senior Services
• Site of the colorectal cancer screening program: St. Louis
• Service delivery network: A specialty care health provider network, a uni-
versity hospital,  and federally qualified health centers
• Screening tests offered: for persons at average risk for colorectal cancer, 
primary screening with guaiac-based fecal occult blood test (FOBT) with 
colonoscopy for follow-up of positive FOBTs; for people at high risk for 
colorectal cancer, primary screening with colonoscopy
• Focus on African Americans
Nebraska Department of Health and Human Services 
• Site of the colorectal cancer screening program: statewide 
• Service delivery network: state health department and physician prac-
tices; some providers already in the National Breast and Cervical Cancer 
Early Detection Program
• Screening tests offered: for persons at average risk for colorectal cancer, 
primary screening with guaiac-based fecal occult blood test (FOBT) with 
colonoscopy for follow-up of positive FOBTs; for people at high risk for 
colorectal cancer, primary screening with colonoscopy
Public Health – Seattle & King County, Washington
• Site of the colorectal cancer screening program: King, Clallam, and 
Jefferson counties 
• Service delivery network: primary care clinics and physician practices; 
some providers already in the National Breast and Cervical Cancer Early 
Detection Program
• Screening tests offered: for persons at average risk for colorectal cancer, 
primary screening with guaiac-based fecal occult blood test (FOBT) with 
colonoscopy for follow-up of positive FOBTs; for people at high risk for 
colorectal cancer, primary screening with colonoscopy
• Focus on American Indians, Alaska Natives and African Americans
Stony Brook University Medical Center/SUNY, New York
• Site of the colorectal cancer screening program: Suffolk County, New 
York
• Service delivery network: Stony Brook University Medical Center 
with referrals from clinics associated with the Suffolk County Health 
Department
• Screening test offered: Primary screening with colonoscopy
Figure. Colorectal Cancer Demonstration Screening Sites, 2005–2008 
Note: All programs provide screening and follow-up services to low-income 
persons aged 50–6 years, who are underinsured or uninsured for colorec-
tal cancer. In addition, some programs focus on a specific demographic 
subgroup. Visit the online version of this article to view the interactive ver-
sion of this map. This page is included as a service to PDF readers.
program participants, an extensive data dictionary, and 
software to validate the data set being submitted. Because 
of the short time frame and limited number of awardees 
participating in the program, we did not provide a stan-
dard data management system. 
Quality assurance 
Several measures were taken to emphasize the impor-
tance of delivering high-quality clinical services. Programs 
were made aware of important quality issues, including 
the frequent and inappropriate use of in-office rather 
than at-home fecal occult blood tests (FOBT) (17), wide 
variation in adenoma detection rates among endoscopists, 
and too-frequent surveillance following polyp detection 
(18). Teleconferences were conducted with CDC staff, 
endoscopists at all five sites, and a leading expert in 
assessing the quality of colorectal cancer screening about 
issues of quality and colonoscopy reporting guidelines. 
Programs and their participating endoscopists were 
encouraged to monitor their performance and follow the 
new standard colonoscopy reporting system (CO-RADS) 
(19), which specifies which elements should be includ-
ed in colonoscopy reports, provides a standard method 
for reporting them, and specifies the key quality indi-
cators that endoscopists should monitor periodically. 
The CCDEs include several factors that allow the qual-
ity of endoscopic services to be measured (e.g., whether 
the bowel preparation was adequate, whether the 
cecum was reached, whether polyps were completely 
removed).
Public education materials 
CDC’s Screen for Life: National Colorectal Cancer Action 
Campaign (SFL) (http://www.cdc.gov/cancer/colorectal/sfl/) 
is a multimedia campaign that promotes colorectal cancer 
screening for adults aged 50 years or older. Programs were 
not required to use SFL materials, but materials that 
could be adapted for local use were developed by CDC staff 
and made available to the five programs. During start-up, 
two sites used the SFL materials and worked with CDC 
to adapt the SFL logo for their own program’s use. Later, 
a third program elected to use SFL materials for patient 
education.
Readiness checklist 
CDC developed a readiness checklist http://www.cdc.
gov/cancer/colorectal/what_cdc_is_doing/demonstration/ 
to be used during start-up to assist CDC and the five 
sites to monitor progress toward implementing the pro-
gram. The items in the checklist corresponded to program 
components and include providing screening and diag-
nostic follow-up services, public education and outreach, 
data collection and tracking, patient support, partnership 
development and maintenance, quality assurance and pro-
fessional development, and program management.
Evaluation 
A comprehensive evaluation of the colorectal cancer 
screening program is being conducted. It will provide 
information to guide our next steps. Evaluators engaged 
program and CDC stakeholders in developing a multisite 
and multiple-method evaluation to assess the program’s 
implementation, outcomes, and efficiencies. Qualitative 
and quantitative evaluation approaches will be used 1) 
to analyze patient screening and diagnostic services, 2) to 
determine cost and cost-effectiveness, and 3) to conduct a 
longitudinal multiple-case study.
State Programs
Colorectal cancer screening is rapidly becoming a prior-
ity at the local, state, and national levels. Several states 
(e.g., New York, Maryland) have long-standing programs; 
other states and cities (e.g., Colorado, New York City) 
recently began colorectal cancer screening; and oth-
ers (e.g., Iowa, Wyoming) are planning to allocate new 
resources for organized colorectal cancer screening pro-
grams. CDC is working closely with the five demonstra-
tion program sites and communicating with other local 
and state partners who are taking steps toward establish-
ing local or state programs so that lessons learned can be 
disseminated widely. Several pieces of legislation have 
been introduced into the U.S. Congress that, if passed, 
would establish a national colorectal cancer screening 
program.
Program activities for the demonstration sites will 
continue through August 2008. The evaluation findings 
published in this issue of Preventing Chronic Disease 
(13-15) and findings to be reported from the implemen-
tation phase of the demonstration program will be used 
to make adjustments during the demonstration period 
and to guide emerging programs and larger future efforts.
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